Clinical Trial: Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07658976) titled 'Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy' on Oct. 07, 2024.

Brief Summary: Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men

Study Start Date: Sept. 01, 2026

Study Type: INTERVENTIONAL

Condition: HIV Infection Sexually Transmitted Infection

Intervention: DRUG: HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA

Choice of F/TDF, F/TAF, or CAB-LA for HIV prevention

DRUG: STI PEP - Doxycycline as Doxy-PEP

Doxycycline as doxy-PEP for STI preve...